FY2025 · period end Dec '25 · from the 10-K filed Feb 11, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | — | — | $0.00B | $0.00B | $0.00B |
| Operating Income | negative: -$0.00B | negative: -$0.00B | negative: -$0.01B | negative: -$0.02B | negative: -$0.01B |
| Net Income | negative: -$0.00B | negative: -$0.00B | negative: -$0.01B | negative: -$0.02B | negative: -$0.01B |
| EPS (Diluted) | $0.00 | $0.00 | negative: -$0.15 | negative: -$0.26 | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Liabilities | — | $0.00B | $0.00B | $0.00B | $0.00B |
| Stockholders' Equity | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | $0.00B | $0.00B |
| Cash & Equivalents | — | — | — | — | — |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | negative: -$0.00B | $0.00B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | 21.3% | 21.7% |
| Operating Margin | — | — | — | negative: -2410.0% | negative: -6.4% |
| Net Margin | — | — | — | negative: -2410.2% | negative: -6.4% |
| Return on Equity | 26.1% | 14.3% | 3426.9% | negative: -3263.2% | negative: -1195.9% |
| Return on Assets | negative: -439.1% | negative: -93.5% | negative: -15066.2% | negative: -2308.6% | negative: -875.2% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
Who is buying and selling ACRO BIOMEDICAL CO., LTD. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ACBM yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on ACBM and publish the result to your public profile.
Ask about ACRO BIOMEDICAL CO., LTD.
Continue in Workspace — cited answers on ACBM, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001640334-26-001345 | Jun 30, 2026 | Aug 14, 2026 | Aug 13, 2026 23:04 UTC | EDGAR |
| 10-Q | 0001640334-26-000824 | Mar 31, 2026 | May 5, 2026 | May 5, 2026 19:24 UTC | EDGAR |
| 10-K | 0001640334-26-000241 | Dec 31, 2025 | Feb 11, 2026 | Feb 11, 2026 17:47 UTC | EDGAR |
| 10-Q | 0001640334-25-001999 | Sep 30, 2025 | Nov 10, 2025 | Nov 10, 2025 21:26 UTC | EDGAR |
| 10-Q | 0001640334-25-001347 | Jun 30, 2025 | Aug 5, 2025 | Aug 5, 2025 11:10 UTC | EDGAR |
| 10-Q | 0001640334-25-001302 | Mar 31, 2025 | Jul 24, 2025 | Jul 24, 2025 21:23 UTC | EDGAR |
| 10-K | 0001640334-25-001300 | Dec 31, 2024 | Jul 24, 2025 | Jul 24, 2025 21:19 UTC | EDGAR |
| 10-Q | 0001640334-25-001279 | Jun 30, 2024 | Jul 23, 2025 | Jul 23, 2025 18:26 UTC | EDGAR |
| 10-Q | 0001640334-25-001281 | Sep 30, 2024 | Jul 23, 2025 | Jul 23, 2025 18:31 UTC | EDGAR |
| 10-Q | 0001640334-25-001257 | Mar 31, 2024 | Jul 22, 2025 | Jul 22, 2025 19:55 UTC | EDGAR |
| 10-K | 0001640334-25-001245 | Dec 31, 2023 | Jul 18, 2025 | Jul 18, 2025 21:23 UTC | EDGAR |
| 10-Q | 0001640334-25-001169 | Sep 30, 2023 | Jul 11, 2025 | Jul 11, 2025 13:55 UTC | EDGAR |
Direct links to SEC EDGAR. ACBM has additional filings available on the SEC site.
6 numbers ACRO BIOMEDICAL CO., LTD. later changed — same XBRL tag, both filings linked.
Selling, General and Administrative Expense·Q1 2017
Major restatementwas$5.9K
Revised up in a 10-Q.
Interest Expense·FY 2022
Major restatementwas$358
Revised up in a 10-K.
Additional Paid in Capital, Common Stock·As of Sep 30, 2016
Major restatementwas$61.5K
Revised down in a 10-K/A.
Deferred Tax Assets, Operating Loss Carryforwards·As of Sep 30, 2016
Notable restatementwas$30.2K
Revised up in a 10-K/A.
Deferred Tax Assets, Valuation Allowance·As of Sep 30, 2016
Notable restatementwas$30.2K
Revised up in a 10-K/A.
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent·FY 2018
Notable restatementwas0.2pure
Revised up in a 10-KT.
ACBM is not the only one.
See every restatement we've found across the market — or get an alert the next time ACBM revises a number.
Restatements are detected by comparing every vintage of a fact across all of ACRO BIOMEDICAL CO., LTD.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows ACBM's most significant revisions, and a figure absent from it has not been certified as unrevised.
